Flow cytometry analysis of tumor-infiltrating cells demonstrated that cefepime increased dendritic cells, CXCR3+ CD8+ T cells (consistent with TH1-polarized immunity [23]), and IFNγ+ NK cells, whereas rabusertib alone did not (Figure 4C). This evidence concerns the gene CD8A and neoplasm.